Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Top 20 Wellbeing and Wellness Applications for a Sound Way of life - 2Help Your Insusceptibility: Good dieting and Way of life Tips
- 3NASA astronauts to return from space early due to an 'unexpected medical issue.' What happened — and when are they coming home?
- 4Russia’s New KVS Drone May Be Designed To Restore Reach In The FPV War
- 5Minneapolis ICE shooting: Woman dies after federal agent opens fire on her vehicle amid immigration crackdown
- Hot peppers sent him to the ER. Two years later, a ‘ghost bill’ arrived.
- This Week In Space podcast: Episode 187 — An Inspired Enterprise
- The Most Enrapturing Authentic Milestones to Visit
- Vote in favor of your Number one Kind of Shades
- Regeneron's experimental therapy combo effective in untreated cancer patients
- The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
- Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- The most effective method to Go Down Abundance through Ages with Disc Rates
